Rosuvastatin Interactions

Red yeast rice contains monacolin K, a compound chemically identical to a statin, so taking it alongside rosuvastatin stacks a second statin-like HMG-CoA reductase inhibitor on top of the prescription statin. Because rosuvastatin is not broken down by the CYP3A4 enzyme, there is no enzyme-based (pharmacokinetic) interaction; the concern is purely additive statin-class exposure. This modestly raises the combined potential for statin-type muscle injury (myopathy, and rarely rhabdomyolysis) and liver injury beyond either agent alone. The added statin burden is usually small because red yeast rice's monacolin content is typically low, highly variable, and not shown on the label, but unregulated high-monacolin products can carry a more meaningful statin-like load.

Rosuvastatin blocks HMG-CoA reductase, the enzyme that makes both cholesterol and coenzyme Q10, so it modestly lowers circulating CoQ10. The depletion is generally smaller than with fat-soluble statins, and mitochondrial impairment is only one proposed mechanism for statin-associated muscle symptoms. This is a possible-benefit pairing, not a dangerous one.

Rosuvastatin is carried into liver cells by the OATP1B1 transporter. In a laboratory study using human liver-cell cultures, berberine increased OATP1B1 activity and pushed more rosuvastatin into the cells. This is an early, test-tube signal only: there is no human or animal data showing it changes blood levels, cholesterol response, or side-effect risk in real life.